Biohaven licensing deal with SK Biopharm for Opakalim platform
Biohaven entered a global licensing agreement with SK Biopharm for its Kv7 ion channel platform and Opakalim, with a $350M upfront payment at closing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.